Skip to main content
SpringerLink
Log in

Principles of Intraperitoneal Chemotherapy

  • Chapter
  • First Online:
Intraperitoneal Therapy for Ovarian Cancer

  • 447 Accesses

Abstract

Despite the completion and publication of the results of three well-designed and conducted phase III randomized trials that revealed the superiority of intraperitoneal, compared to intravenous cisplatin-based chemotherapy employed as primary chemotherapy of small-volume residual advanced ovarian cancer [1–3], there appears to be limited use of this approach outside the setting of clinical trials and major academic medical centers. While a variety of explanations can be offered to this somewhat discouraging state of affairs, it is reasonable to speculate that many clinicians do not fully appreciate the underlying rationale and basic principles supporting this method of drug delivery in the management of ovarian cancer. Such considerations actually provide strong support for the validity of the outcomes observed in the completed randomized trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950–1955

    Article  PubMed  CAS  Google Scholar 

  2. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43

    Article  PubMed  CAS  Google Scholar 

  3. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001–1007

    PubMed  CAS  Google Scholar 

  4. Suhrland LG, Weisberger AS (1965) Intracavitary 5-fluorouracil in malignant effusions. Arch Intern Med 116:431–433

    Article  PubMed  CAS  Google Scholar 

  5. Weisberger AS, Levine B, Storaasli JP (1955) Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA 159:1704–1707

    Article  CAS  Google Scholar 

  6. Dedrick RL (1985) Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 12:1–6

    PubMed  CAS  Google Scholar 

  7. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1–11

    PubMed  CAS  Google Scholar 

  8. Kraft AR, Tompkins RK, Jesseph JE (1968) Peritoneal electrolyte absorption: analysis of portal, systemic venous and lymphatic transport. Surgery 64:148–153

    PubMed  CAS  Google Scholar 

  9. Lukas G, Brindle SD, Greengard P (1971) The route of absorption of intraperitoneally administered compounds. J Pharmacol Exp Ther 178:562–564

    PubMed  CAS  Google Scholar 

  10. Alberts DS, Young L, Mason N, Salmon SE (1985) In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 12:38–42

    PubMed  CAS  Google Scholar 

  11. Andrews PA, Velury S, Mann SC, Howell SB (1988) cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 48:68–73

    PubMed  CAS  Google Scholar 

  12. Gore M, Mainwaring P, A’Hern R, MacFarlane V, Slevin M, Harper P, Osborne R, Mansi J, Blake P, Wiltshaw E, Shepherd J (1998) Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 16:2426–2434

    PubMed  CAS  Google Scholar 

  13. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, Ball H, Berek JS, Woodward J (1995) Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 13:1589–1599

    PubMed  CAS  Google Scholar 

  14. Casper ES, Kelsen DP, Alcock NW, Lewis JL Jr (1983) Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the IV route. Cancer Treat Rep 67:235–238

    PubMed  CAS  Google Scholar 

  15. Degregorio MW, Lum BL, Holleran WM, Wilbur BJ, Sikic BI (1986) Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol 18:235–238

    Article  PubMed  CAS  Google Scholar 

  16. Elferink F, van der Vijgh WJ, Klein I, ten Bokkel Huinink WW, Dubbelman R, McVie JG (1988) Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol 21:57–60

    Article  PubMed  CAS  Google Scholar 

  17. Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97:845–851

    PubMed  CAS  Google Scholar 

  18. Lopez JA, Krikorian JG, Reich SD, Smyth RD, Lee FH, Issell BF (1985) Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol 20:1–9

    Article  PubMed  CAS  Google Scholar 

  19. Pretorius RG, Hacker NF, Berek JS, Ford LC, Hoeschele JD, Butler TA, Lagasse LD (1983) Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep 67:1085–1092

    PubMed  CAS  Google Scholar 

  20. Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332:1004–1014

    Article  PubMed  CAS  Google Scholar 

  21. Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M (1995) Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group Pilot study. J Clin Oncol 13:2961–2967

    PubMed  CAS  Google Scholar 

  22. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, Rubin S, Curtin J, Barakat R, Phillips M et al (1992) Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol 10:1485–1491

    PubMed  CAS  Google Scholar 

  23. Litterst CL, Collins JM, Lowe MC, Arnold ST, Powell DM, Guarino AM (1982) Local and systemic toxicity resulting from large-volume Ip administration of doxorubicin in the rat. Cancer Treat Rep 66:157–161

    PubMed  CAS  Google Scholar 

  24. Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC (1979) Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 39:3209–3214

    PubMed  CAS  Google Scholar 

  25. Markman M, George M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr (1990) Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. J Clin Oncol 8:146–150

    PubMed  CAS  Google Scholar 

  26. Roboz J, Jacobs AJ, Holland JF, Deppe G, Cohen CJ (1981) Intraperitoneal infusion of doxorubicin in the treatment of gynecologic carcinomas. Med Pediatr Oncol 9:245–250

    Article  PubMed  CAS  Google Scholar 

  27. Litterst CL, Torres IJ, Arnold S, McGunagle D, Furner R, Sikic BI, Guarino AM (1982) Absorption of antineoplastic drugs following large-volume Ip administration of rats. Cancer Treat Rep 66:147–155

    PubMed  CAS  Google Scholar 

  28. Durand RE (1981) Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro. Cancer Res 41:3495–3498

    PubMed  CAS  Google Scholar 

  29. Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG (1989) Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49:3380–3384

    PubMed  CAS  Google Scholar 

  30. Los G, Verdegaal EM, Mutsaers PH, McVie JG (1991) Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 28:159–165

    Article  PubMed  CAS  Google Scholar 

  31. West GW, Weichselbau R, Little JB (1980) Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res 40:3665–3668

    PubMed  CAS  Google Scholar 

  32. Covens A, Carey M, Bryson P, Verma S, Fung Kee FM, Johnston M (2002) Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 85:71–80

    Article  PubMed  CAS  Google Scholar 

  33. Markman M (2008) Critical thinking: an essential role in both the conduct and interpretation of gynecologic cancer clinical research. Gynecol Oncol 108:462–465

    Article  PubMed  Google Scholar 

  34. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC (1998) A phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube and peritoneum: a Gynecologic Oncology Group study. J Clin Oncol 16:2620–2624

    PubMed  CAS  Google Scholar 

  35. Krasner CN, Seiden MV, Fuller AF, Roche M, Verrill CL, D’Amato F, Tretyakov O, Tyburski K, Matulonis UA, Supko JG (2006) Pharmacokinetic analysis of an all intraperitoneal carboplatin and paclitaxel regimen in ovarian cancer patients demonstrates favorable systemic bioavailability of both agents. J Clin Oncol 24(18S):257

    Google Scholar 

  36. Walker JL, Armstrong D, Huang HQ, Fowler J, Webster K, Burger R, Clarke-Pearson D (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus ­intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 100:27–32

    Article  PubMed  Google Scholar 

  37. Bergman F (1966) Carcinoma of the ovary: a clinicopathological study of 86 autopsied cases with special reference to mode of spread. Acta Obstet Gynecol Scand 45:211–231

    Article  PubMed  CAS  Google Scholar 

  38. Dauplat J, Hacker NF, Nieberg RK, Berek JS, Rose TP, Sagae S (1987) Distant metastases in epithelial ovarian carcinoma. Cancer 60:1561–1566

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecologic Medical Oncology, The University of Texas M.D.Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

    Maurie Markman

Authors
  1. Maurie Markman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maurie Markman .

Editor information

Editors and Affiliations

  1. College of Medicine, Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA

    David S. Alberts

  2. Arizona Cancer Center, University of Arizona, N. Campbell Ave. 1515, Tucson, 85724-5024, Arizona, USA

    Mary C. Clouser

  3. School of Medicine, Deps of Pub. Health and Obstetrics and G, Indiana University, N. Senate Ave. EF250 714, Indianapolis, IN, 46202, Arizona, USA

    Lisa M. Hess

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Markman, M. (2010). Principles of Intraperitoneal Chemotherapy. In: Alberts, D., Clouser, M., Hess, L. (eds) Intraperitoneal Therapy for Ovarian Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12130-2_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-12130-2_3

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-12129-6

  • Online ISBN: 978-3-642-12130-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation